ArticleJournal of the Endocrine Society2023
Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis.
Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Growth Hormone Treatment Response and Machine Learning-Based Prediction in Idiopathic GHD and ISS: Analysis of the Korean LG Growth Study.Clinical endocrinology · 2026Observational
- Association of Growth Hormone Adherence and Growth Outcomes in Paediatric Patients: Results From a Clinical Registry.Clinical endocrinology · 2026Article
- Predictors of Response to Growth Hormone Therapy in Children with Idiopathic Growth Hormone Deficiency: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Growth Hormone Response in a Child With a Homozygous TOMM7 Mutation: Novel Therapeutic Insights.The American journal of case reports · 2025Article
- Real-World Evidence of Treatment Patterns and Costs of Turner Syndrome and Noonan Syndrome in the USA.Hormone research in paediatrics · 2025Article
- Growth hormone regulates the stem cell population in the growth plate.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Nutritional Counseling in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: Analysis of Growth Response Parameters.Biomedicines · 2025Article
- Identification ofInternational journal of molecular sciences · 2025Article
- Metabolic factors influencing the efficacy of recombinant human growth hormone therapy in children with short stature.Frontiers in endocrinology · 2025Article
- Noonan Syndrome Growth Charts and Genotypes: 15-Year Longitudinal Single-Centre Study.Hormone research in paediatrics · 2025Observational
- What Factors Spur a Short Individual's Response to Human GH (hGH)?Journal of the Endocrine Society · 2023Article
- Growth Outcomes and Safety of Recombinant Growth Hormone in Noonan Syndrome: A Systematic Review and Meta-Analysis.Indian journal of endocrinology and metabolismReview
Corrections and comments
- Commented on by
Authors and funding
10 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective: To assess growth and identify factors associated with growth response with long-term GH therapy. Methods: Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results: Data from patients with GHD (n = 12 683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on Conclusion: Long-term GH therapy results in large increases in HSDS in patients with GHD, TS, NS, and PWS. Greater gains in HSDS can be obtained with higher GH doses and earlier initiation of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.